Haisch · American journal of physiology. Endocrinology and metabolism 2000 · crossover metabolic tracer study · n=5

Oxidation of glutamine by the splanchnic bed in humans.

Cited 69 times in the scientific literature.

Level 3 - non-randomized controlled study

Small crossover physiological tracer study in healthy human volunteers

PubMed 10751191 · doi:10.1152/ajpendo.2000.278.4.E593 · record verified 2026-08-30

What was done

Five postabsorptive healthy volunteers completed two 7-hour dual-tracer infusions of [1,2-13C2]glutamine and [ring-2H5]phenylalanine. On each occasion, tracers were administered for 3.5 hours intravenously and 3.5 hours via nasogastric tube in a crossed-over sequence. Splanchnic first-pass uptake, whole-body glutamine flux, tracer oxidation (via exhaled 13CO2), and conversion into plasma glucose were quantified at isotopic plateau.

What was found

First-pass splanchnic extraction removed 27 ± 2% of enteral phenylalanine and 64 ± 2% of enteral glutamine. Total glutamine flux was 303 ± 8 µmol·kg⁻¹·h⁻¹. Exhaled 13CO2 recovery was 73 ± 2% for enteral versus 58 ± 1% for intravenous tracer. The fraction of enteral glutamine oxidized directly on first pass by the splanchnic bed was 53 ± 2%, accounting for 83% of the extracted tracer. Incorporation into plasma glucose was 7% for intravenous and 10% for nasogastric glutamine.

Why it matters

This study provides direct human quantitative evidence that the major metabolic fate of enterally absorbed glutamine during first-pass splanchnic transit is energy production via oxidation, with only a small portion directed toward gluconeogenesis.

Limits

The study is restricted by a very small sample size (n = 5) and evaluated only healthy subjects in the postabsorptive state. Splanchnic measurements reflect combined gut and liver metabolism without distinguishing gut-specific mucosal oxidation from hepatic uptake.

Cited by